Abstract:ID 92155 Poster Board 478 The Glucagon-like peptide 1 receptor (GLP-1R) belongs to the Class B G-protein coupled receptors (GPCRs) and is a well-established target for treating type 2 diabetes. Recent clinical-trial data suggest that GLP-1R agonistic drugs not only significantly reduce body weight in individuals with obesity, but may also offer protection against serious heart disease and drug/alcohol addiction related issues. Consequently, GLP-1R has become one of the most intriguing and extensively studied Class B GPCRs. Although GLP-1R agonist-based therapies, including various GLP-1 analog drugs, are highly successful and available in the market, most are peptidic in nature and require intravenous ( iv ) mode of administration. Thus, it remains a challenge to develop nonpeptidic agonist drugs targeting GLP-1R. A promising approach, involves the development of small molecule positive allosteric modulators (PAMs) of GLP-1R, which have a greater potential for more convenient oral ( po ) administration. Building upon our prior work that identified two 2-aminothiophene-based small-molecule PAMs of GLP-1R, we conducted a series of structural SAR optimizations, as well as in vitro and in vivo studies. This effort led to the identification of 2-aminothiophene derivative, I-187 (MW 299), which exhibited an approximately 2-fold increase in insulin secretion at 5 μM when combined with the GLP-1 peptide at 10 nM. I n vivo studies using CD1 mice revealed a 50% reduction in glucose levels after 60 minutes at a dose of 10 mg/kg b.w. More notably, co-treatment with sitagliptin, an inhibitor of the GLP-1 degrading enzyme dipeptidyl peptidase IV, demonstrated that I-187 synergistically lowered blood glucose levels by approximately 75% after 60 minutes, confirming its effectiveness as a PAM of GLP-1R. These promising results, coupled with the favorable drug-like properties of the compound, suggest that I-187 is a compelling lead compound for future drug development. Furthermore, this approach can potentially be applied to the development of allosteric modulation of other GPCRs. This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R15GM140406.

Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723.

Discovery of Novel Dual-Action Antidiabetic Agents That Inhibit Glycogen Phosphorylase and Activate Glucokinase

Synthesis and Biological Evaluation of Ursolic Acid Derivatives As Novel Inhibitors of Glycogen Phosphorylase

Recent Advances in Design of Glycogen Phosphorylase Inhibitors

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.

Synthesis and biological evaluation of asiatic acid derivatives as inhibitors of glycogen phosphorylases.

Small Molecules As Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013

A New Potent Inhibitor Against Α-Glucosidase Based on an in Vitro Enzymatic Synthesis Approach

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

Synthesis and Evaluation of Novel Oleanolic Acid Derivatives As Potential Antidiabetic Agents

Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications

Synthesis, In Silico and Kinetics Evaluation of N-(β-d-glucopyranosyl)-2-arylimidazole-4(5)-carboxamides and N-(β-d-glucopyranosyl)-4(5)-arylimidazole-2-carboxamides as Glycogen Phosphorylase Inhibitors

Design, Synthesis of a Novel Phosphatase 1B Inhibitor and the Evaluation of Its Biology Activity and Toxicity in vitro

Myricetin: a Potent Approach for the Treatment of Type 2 Diabetes As a Natural Class B GPCR Agonist.

Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes

Identification of Pentacyclic Triterpenes Derivatives As Potent Inhibitors Against Glycogen Phosphorylase Based on 3D-QSAR Studies

Non‐peptide agonists and positive allosteric modulators of glucagon‐like peptide‐1 receptors: Alternative approaches for treatment of Type 2 diabetes

Design, Synthesis, and Biological Evaluations of Phenylpropiolic Acid Derivatives As Novel GPR40 Agonists

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

Unlocking potential diabetes therapeutics: Insights into alpha-glucosidase inhibition